CHMFL-ABL-053BCR-ABL inhibitor CAS# 1808287-83-3 |
- 3,3'-Diindolylmethane
Catalog No.:BCC1306
CAS No.:1968-05-4
- BAM7
Catalog No.:BCC1397
CAS No.:331244-89-4
- Bendamustine HCl
Catalog No.:BCC1153
CAS No.:3543-75-7
- Betulinic acid
Catalog No.:BCN5524
CAS No.:472-15-1
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1808287-83-3 | SDF | Download SDF |
| PubChem ID | 122634050 | Appearance | Powder |
| Formula | C28H26F3N7O2 | M.Wt | 549.55 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| Chemical Name | 2-(3-amino-4-methylanilino)-4-(methylamino)-N-[2-methyl-5-[[3-(trifluoromethyl)benzoyl]amino]phenyl]pyrimidine-5-carboxamide | ||
| SMILES | CC1=C(C=C(C=C1)NC2=NC=C(C(=N2)NC)C(=O)NC3=C(C=CC(=C3)NC(=O)C4=CC(=CC=C4)C(F)(F)F)C)N | ||
| Standard InChIKey | GXMFPDCIAWSZFR-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C28H26F3N7O2/c1-15-7-9-19(12-22(15)32)36-27-34-14-21(24(33-3)38-27)26(40)37-23-13-20(10-8-16(23)2)35-25(39)17-5-4-6-18(11-17)28(29,30)31/h4-14H,32H2,1-3H3,(H,35,39)(H,37,40)(H2,33,34,36,38) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
CHMFL-ABL-053 Dilution Calculator
CHMFL-ABL-053 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8197 mL | 9.0984 mL | 18.1967 mL | 36.3934 mL | 45.4918 mL |
| 5 mM | 0.3639 mL | 1.8197 mL | 3.6393 mL | 7.2787 mL | 9.0984 mL |
| 10 mM | 0.182 mL | 0.9098 mL | 1.8197 mL | 3.6393 mL | 4.5492 mL |
| 50 mM | 0.0364 mL | 0.182 mL | 0.3639 mL | 0.7279 mL | 0.9098 mL |
| 100 mM | 0.0182 mL | 0.091 mL | 0.182 mL | 0.3639 mL | 0.4549 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
CHMFL-ABL-053 (compound 18a) is a BCR-ABL inhibitor with ABL1: IC50 of 70 nM. CHMFL-ABL-053 is derived from a dihydropyrimidopyrimidine core scaffold based compound 27 (GNF 7). [1]
CHMFL-ABL-053 inhibited the proliferation of CML cell lines K562 (GI50 = 14 nM), KU812 (GI50 = 25 nM) and MEG 01 (GI50 = 16 nM), through significant suppression of the BCR-ABL auto phosphorylation (EC50 = 100 nM) and downstream mediators such as STAT5, Crkl and ERK’s phosphorylation. In the TEL fused isogenic BaF3 cells, CHMFL-ABL-053 exhibited strong binding ability against BLK, DDR1, DDR2, EPHA8, EphB6, HCK, LCK, p38α and SRC kinases. CHMFL-ABL-053 exhibited an IC50 of 70 nM against ABL1 kinase, inhibited p38α (IC50: 62 nM) and SRC kinase (IC50: 90 nM) by Invitrogen Select Screen biochemical assay. CHMFL-ABL-053 showed less potent to DDR1 (IC50: 292 nM) and DDR2 (IC50: 457 nM). CHMFL-ABL-053 did not exhibit apparent potency against c-KIT kinase (IC50: over 10000 nM). [1]
Pharmacokinetic study showed that CHMFL-ABL-053 had over 4 hours half-life and 24% bioavailability in rats. 50mg/kg/day dosage treatment could almost completely suppress the tumor progression in the K562 cells inoculated xenograft mouse model. As a potential useful drug candidate for CML, 18a is under extensive preclinical safety evaluation now. [1]
Reference:
1.Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl) benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.J Med Chem. 2016 Feb 5. [Epub ahead of print]
- LG 100754
Catalog No.:BCC7786
CAS No.:180713-37-5
- Polypodine B
Catalog No.:BCN8117
CAS No.:18069-14-2
- 1,4-Bis(5-phenyl-2-oxazolyl)benzene
Catalog No.:BCC8424
CAS No.:1806-34-4
- 2,2'-Biphenol
Catalog No.:BCC8488
CAS No.:1806-29-7
- Peiminine
Catalog No.:BCN1095
CAS No.:18059-10-4
- Gentioflavin
Catalog No.:BCN3619
CAS No.:18058-50-9
- Fmoc-D-Asn(Trt)-OH
Catalog No.:BCC3084
CAS No.:180570-71-2
- Solifenacin hydrochloride
Catalog No.:BCC5193
CAS No.:180468-39-7
- Perillaldehyde
Catalog No.:BCN8294
CAS No.:18031-40-8
- Cyclo(Leu-Ala)
Catalog No.:BCN2428
CAS No.:1803-60-7
- NCT-501
Catalog No.:BCC6539
CAS No.:1802088-50-1
- Phytolaccagenin
Catalog No.:BCN1140
CAS No.:1802-12-6
- 4-O-Caffeoylshikimic acid
Catalog No.:BCN7931
CAS No.:180842-65-3
- Jaceosidin
Catalog No.:BCN2529
CAS No.:18085-97-7
- Spiramilactone B
Catalog No.:BCN1141
CAS No.:180961-65-3
- Neuchromenin
Catalog No.:BCN7449
CAS No.:180964-26-5
- FTI 277 HCl
Catalog No.:BCC6395
CAS No.:180977-34-8
- 3-O-Caffeoylshikimic acid
Catalog No.:BCN7930
CAS No.:180981-12-8
- Curcumaromin A
Catalog No.:BCN7417
CAS No.:1810034-38-8
- Curcumaromin B
Catalog No.:BCN7419
CAS No.:1810034-39-9
- Curcumaromin C
Catalog No.:BCN7418
CAS No.:1810034-40-2
- Corymbosin
Catalog No.:BCN6812
CAS No.:18103-41-8
- 5,7-Dihydroxy-3',4',5'-trimethoxyflavone
Catalog No.:BCN6807
CAS No.:18103-42-9
- Proflavine Hemisulfate
Catalog No.:BCC4707
CAS No.:1811-28-5
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phe nyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.[Pubmed:26789553]
J Med Chem. 2016 Mar 10;59(5):1984-2004.
Starting from a dihydropyrimidopyrimidine core scaffold based compound 27 (GNF-7), we discovered a highly potent (ABL1: IC50 of 70 nM) and selective (S score (1) = 0.02) BCR-ABL inhibitor 18a (CHMFL-ABL-053). Compound 18a did not exhibit apparent inhibitory activity against c-KIT kinase, which is the common target of currently clinically used BCR-ABL inhibitors. Through significant suppression of the BCR-ABL autophosphorylation (EC50 about 100 nM) and downstream mediators such as STAT5, Crkl, and ERK's phosphorylation, 18a inhibited the proliferation of CML cell lines K562 (GI50 = 14 nM), KU812 (GI50 = 25 nM), and MEG-01 (GI50 = 16 nM). A pharmacokinetic study revealed that 18a had over 4 h of half-life and 24% bioavailability in rats. A 50 mg/kg/day dosage treatment could almost completely suppress tumor progression in the K562 cells inoculated xenograft mouse model. As a potential useful drug candidate for CML, 18a is under extensive preclinical safety evaluation now.
